Canakinumab (60), an anti-inflammatory drug, has been shown to significantly reduce the risk of recurrent cardiovascular events, including stroke, in patients with a history of myocardial infarction and elevated levels of hs-CRP. The gene discussed is CRP; the disease is myocardial infarction.